CN102824614A - Application of Wujin tablets for preparing medicines for suppressing PC-3 cell proliferation - Google Patents
Application of Wujin tablets for preparing medicines for suppressing PC-3 cell proliferation Download PDFInfo
- Publication number
- CN102824614A CN102824614A CN2012103515405A CN201210351540A CN102824614A CN 102824614 A CN102824614 A CN 102824614A CN 2012103515405 A CN2012103515405 A CN 2012103515405A CN 201210351540 A CN201210351540 A CN 201210351540A CN 102824614 A CN102824614 A CN 102824614A
- Authority
- CN
- China
- Prior art keywords
- tablets
- wujin
- cell proliferation
- rhizoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of Wujin tablets for preparing medicines for suppressing PC-3 cell proliferation. The formula of the Wujin tablets comprises the components of pollen typhae, plant soot, leonurus, prepared rehmannia root, charred folium artemisiae argyi, rhizoma sparganii, rhizoma corydalis, rhizoma cyperi, white paeony root, fructus psoraleae, fructus evodiae, rhizoma chuanxiong, curcuma zedoary, elecampane, angelica sinensis and fennel oil. The Wujin tablets have the effects of regulating menstruation and removing stasis and are used for qi depression hysteresis, chest and hypochondrium pain, postpartum blood stasis, lower abdomen pain, dysphoria in chestpalms-soles and emaciation with sallow complexion, the specification is 0.6g per tablet, the tablets are taken orally, four tablets are taken once in the mode of two times per day. The tablets can suppress the PC-3 cell proliferation.
Description
Technical field
The present invention relates to a kind of new purposes of Chinese patent medicine, relate in particular to the coal sheet and suppress the application in the PC-3 cell proliferation medicine in preparation.
Background technology
Carcinoma of prostate is exactly the malignant tumor that betides in the male prostate tissue, is the result of the unusual unordered growth of prostate acinous cell.The sickness rate of carcinoma of prostate has tangible geography and race difference.In developed country and areas such as America and Europes, it is the modal malignant tumor of male, and its mortality rate occupies second of various cancers; In the Asia, its sickness rate is lower than western countries, but is rapid ascendant trend in recent years.
The coal sheet is the exclusive product of Yunnan Prov YongZiTang Pharmaceutical Co., Ltd, does not also have it to suppress the bibliographical information of carcinoma of prostate (PC-3) cell proliferation at present.
Summary of the invention
Goal of the invention: the object of the present invention is to provide the coal sheet to suppress the application in the PC-3 cell proliferation medicine in preparation.
Technical scheme: the coal sheet suppresses the application in the PC-3 cell proliferation medicine in preparation.
The coal tablet recipe is Pollen Typhae, Pulvis Fumi Carbonisatus, Herba Leonuri, Radix Rehmanniae Preparata, Folium Artemisiae Argyi (charcoal), triangular, Rhizoma Corydalis, Rhizoma Cyperi, the Radix Paeoniae Alba, Fructus Psoraleae, Fructus Evodiae, Rhizoma Chuanxiong, Rhizoma Curcumae, the Radix Aucklandiae, Radix Angelicae Sinensis, fennel oil, and regulating menstruation and absorbing clots is used for stagnation of QI knot and stagnates, the twinge of the breast side of body; Postnatal blood stasis, lower abdomen pain, dysphoria with feverish sensation in the chest palms and soles; Emaciation and sallow complexion, specification is every 0.6g, and is oral; One time 4,2 times on the one, find that at present it can suppress the PC-3 cell proliferation.
Beneficial effect: the coal sheet suppresses the PC-3 cell proliferation, and is respond well.
The specific embodiment
The coal sheet suppresses the experimentation data of PC-3 cell proliferation
1 experiment material
1.1 cell strain is used in experiment
Carcinoma of prostate (PC-3), from our company's laboratory cell bank, DMEM+10%FBS is conventional to be cultivated.
1.2 experiment medicine
Research medicine: coal sheet, Yunnan Prov YongZiTang Pharmaceutical Co., Ltd, lot number: 20110423
The medicinal liquid liquid storage: take by weighing 100mg coal sheet and pulverize, be dissolved in the 5ml dehydrated alcohol, 0.2 μ m filter filters, and 500 μ l doff manage packing ,-20 ℃ of storages, and 0.2 μ m filter filters the usefulness of dehydrated alcohol in order to matched group simultaneously.
1.3 experiment reagent
DMEM (the Cat.No.12100-061 Lot.No.758137 of GIBCO company); Hyclone (Hangzhoupro, sky, Zhejiang bio tech ltd Lot.No.100419); NaHCO3 (Shanghai hundred million chemical reagent company limited Cat.No.11810-033Lot.No.1088387 of a specified duration); Trypsin (AMRESCO company lot number: 2010/04); EDTA (AMRESCO company lot number: 2009/10); Penicillin G Sodium Salt (AMRESCO company lot number: 2010242); Streptomycin Sulfate (AMRESCO company lot number: 2010382); Dehydrated alcohol (Nanjing Chemistry Reagent Co., Ltd.'s lot number: 080310182); MTT (Biosharp lot number: 0793); PBS (laboratory autogamy);
1.4 experiment equipment
Lycra inverted microscope (German Leica model: DM1L); It is thus clear that-ultraviolet light microwell plate detector (U.S. MD company model: SPECTRAMAX 190); CO2 incubator (FORMA model: 3111); Super-clean bench (the safe and sound manufactured model of Su Jing group: SW-CJ-ZFD); Pure water appearance (U.S. Spring company model: S/N 020579); Accurate pipettor (French Gilson Inc model: P2); Electronic balance (German Sai Duolisi company limited model: BT323S); Full-automatic high-pressure autoclave (Japanese SANYO company model: MLS-3020); Desk-top electric drying oven with forced convection (the accurate experimental facilities in Shanghai company model: DHG9123A); Refrigerator (Siemens Company's model: KG18V21TI); Liquid nitrogen container (CBS model: 2001); Low speed centrifuge (Anting Scientific Instrument Factory, Shanghai's model: KA-1000); 0.2 μ m filter (MILLIPORE model: SLGP033RB); 10cm culture dish (NEST company), 96 well culture plates (NEST company); Cell counting count board; Centrifuge tube, pipet, Tips are some.
2 experimental techniques
1) the PC-3 cell carries out routine with DMEM+10%FBS in 37 ℃, 5%CO2 and cultivates (10cm culture dish), when cell grows to logarithmic (log) phase, and collecting cell; Discard culture fluid, PBS fine laundering 3 times adds 3ml 0.25% trypsin-0.04%EDTA; Behind 37 ℃ of digestion 2min,, behind the piping and druming cell it is changed in the centrifuge tube to wherein adding 5ml complete medium neutralization reaction; The centrifugal 5min of 1000rpm, 3 * 104/ml of adjustment concentration of cell suspension.
2) the cell kind is gone in 96 well culture plates, every hole adds cell suspension 180 μ l, and culture plate is put into cell culture incubator, and (37 ℃, 5%CO2) routine is cultivated.
3) according to the cell growing state, generally grow to 50%-70%, add coal sheet solution, continue to cultivate 24h.
4) add 20 μ l MTT solution (5mg/ml, i.e. 0.5%MTT) behind the 24h, continue to cultivate 4h.
5) the buckle method is removed supernatant behind the 4h, claps driedly gently with absorbent paper, and every hole adds 200 μ l dimethyl sulfoxide, puts low-speed oscillation 10min on the shaking table, and crystal is fully dissolved.Measure the light absorption value in each hole at enzyme-linked immunosorbent assay instrument 490nm place.
6) background (do not add cell, only add culture fluid) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, culture fluid, MTT, dimethyl sulfoxide), 6 multiple holes of every settings.
7) result representes with the suppression ratio of medicine pair cell:
Cell increment suppression ratio (%)=(control wells OD value-dosing holes OD value)/control wells OD value * 100%.Experiment repetition 3 times.
3 statistical dispositions
Adopt correlation analysis and Student t check in Microsoft Excel 2003 softwares, data are represented with mean ± S.D..
4 experimental results
Mtt assay experiment back statistical result showed; Compare with matched group; When dosage reaches 5mg/ml; To PC-3 cell inhibitory effect variant (P < 0.05), dosage this difference when 10mg/>ml has significance (P < 0.01), and utmost point significant difference (P < 0.001) is arranged when dosage reaches 15-20mg/>ml.
Annotate: compare * P < 0.01 with matched group; * P < 0.001
5 experiment conclusion
The coal sheet can suppress the PC-3 cell proliferation, reduces the cell growing number of PC-3 cell, and this effect is time and dose dependent.
Claims (1)
1. the coal sheet suppresses the application in the PC-3 cell proliferation medicine in preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012103515405A CN102824614A (en) | 2012-09-20 | 2012-09-20 | Application of Wujin tablets for preparing medicines for suppressing PC-3 cell proliferation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012103515405A CN102824614A (en) | 2012-09-20 | 2012-09-20 | Application of Wujin tablets for preparing medicines for suppressing PC-3 cell proliferation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102824614A true CN102824614A (en) | 2012-12-19 |
Family
ID=47328060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012103515405A Pending CN102824614A (en) | 2012-09-20 | 2012-09-20 | Application of Wujin tablets for preparing medicines for suppressing PC-3 cell proliferation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102824614A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139238A (en) * | 2023-03-05 | 2023-05-23 | 湖南汉森制药股份有限公司 | Pharmaceutical composition and preparation method thereof |
CN116139239A (en) * | 2023-03-05 | 2023-05-23 | 湖南汉森制药股份有限公司 | Traditional Chinese medicine composition for regulating menstruation and removing blood stasis as well as determination method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036263A (en) * | 1996-07-25 | 1998-02-10 | Kureha Chem Ind Co Ltd | Corydaline derivative-containing synthesis inhibitor of protein belonging to hsp27 family |
CN101219135A (en) * | 2007-01-08 | 2008-07-16 | 杭州民生药业集团有限公司 | Application of zedoary root cyclic diolefine in preparing medicament for treating tumour disease and disease caused by virus |
KR101131224B1 (en) * | 2009-10-12 | 2012-03-28 | 부경대학교 산학협력단 | Coumarin compounds from Corydalis heterocarpa and Anticancer composition containing the same |
-
2012
- 2012-09-20 CN CN2012103515405A patent/CN102824614A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1036263A (en) * | 1996-07-25 | 1998-02-10 | Kureha Chem Ind Co Ltd | Corydaline derivative-containing synthesis inhibitor of protein belonging to hsp27 family |
CN101219135A (en) * | 2007-01-08 | 2008-07-16 | 杭州民生药业集团有限公司 | Application of zedoary root cyclic diolefine in preparing medicament for treating tumour disease and disease caused by virus |
KR101131224B1 (en) * | 2009-10-12 | 2012-03-28 | 부경대학교 산학협력단 | Coumarin compounds from Corydalis heterocarpa and Anticancer composition containing the same |
Non-Patent Citations (4)
Title |
---|
张辉等,: "吴茱萸碱诱导前列腺癌PC-3细胞凋亡机制的实验研究", 《中国老年学杂志》, vol. 27, no. 13, 31 July 2007 (2007-07-31), pages 1230 - 1231 * |
揭金阶等,: "《临床中成药物学》", 31 October 2004, article "乌金片", pages: 424-425 * |
朱晓音等,: "当归提取物对PC3、HeLa、MDA-MB-435 肿瘤细胞增殖的影响", 《山东中医杂志》, vol. 26, no. 11, 30 November 2007 (2007-11-30), pages 776 - 778 * |
陈哲等,: "补骨脂酚对PC-3细胞增殖抑制作用研究", 《中国药学会应用药理专业委员会第三届学术会议、中国药理学会制药工业专业委员会第十三届学术会议暨2008生物医药学术论坛论文汇编 》, 31 July 2008 (2008-07-31), pages 114 - 115 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116139238A (en) * | 2023-03-05 | 2023-05-23 | 湖南汉森制药股份有限公司 | Pharmaceutical composition and preparation method thereof |
CN116139239A (en) * | 2023-03-05 | 2023-05-23 | 湖南汉森制药股份有限公司 | Traditional Chinese medicine composition for regulating menstruation and removing blood stasis as well as determination method and application thereof |
CN116139239B (en) * | 2023-03-05 | 2023-08-22 | 湖南汉森制药股份有限公司 | Traditional Chinese medicine composition for regulating menstruation and removing blood stasis as well as determination method and application thereof |
CN116139238B (en) * | 2023-03-05 | 2023-09-08 | 湖南汉森制药股份有限公司 | Pharmaceutical composition and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103494902B (en) | Preparation method and application of pseudo-ginseng injury tablets | |
CN103784738A (en) | Extraction method and application of plant composition containing Maca | |
CN103816368A (en) | Extraction method and application of ginseng-containing plant composition | |
CN103860802B (en) | Preparation method and application of Jieguqili tablet | |
CN102824614A (en) | Application of Wujin tablets for preparing medicines for suppressing PC-3 cell proliferation | |
CN103494885B (en) | A kind of preparation method of TONGXIAO BIYAN PIAN and application | |
CN103690756B (en) | A kind of application of Qingfeiyihuo Tablets and preparation method | |
CN103520446B (en) | A kind of preparation method of the Zijin ball that bonesets and application | |
CN103550738B (en) | A kind of preparation method of red mast ease pill and application | |
CN103720799A (en) | Preparation method and application of Huoluo Xiaotong tablets | |
CN103536733B (en) | Preparation method and application of rhizoma cyperi pill with ten precious materials | |
CN102824406B (en) | The red capsule for freeing collateral vessels of dragon suppresses the application in MJ cell proliferation in preparation | |
CN103690601A (en) | Application and preparation method of heart strengthening tablets | |
CN103494915A (en) | Preparation method and application of breast lump dissipating tablet | |
CN102836261B (en) | Application of kidney-tonifying capsules in preparing medicament for inhibiting MDA-MB-157 cell proliferation | |
CN102824515A (en) | Application of Reduqing pills in preparation of medicine for inhibiting A-204 cell proliferation | |
CN105056105B (en) | A kind of preparation method and application of shenmei stomach nourishing granule | |
CN103638489B (en) | Preparation method and application of kidney-tonifying pills | |
CN103610857B (en) | A kind of preparation method and application of returning red pill for traumatic injuries | |
CN104906260A (en) | Preparation method and application of wind-expelling and itching-relieving granule | |
CN103656016B (en) | A kind of preparation method of antiasthmatic pill of perilla fruit and application | |
CN103656181B (en) | A kind of application of tablet for women's health and tranquilness and preparation method | |
CN103638487B (en) | A kind of preparation method of Babao Ruisheng pill and application | |
CN103721136A (en) | Preparation method and application of pharyngitis tablet | |
CN103536654A (en) | Preparation method and application of blended pill of ligusticum wallichii and tea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121219 |